S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery
|ClinicalTrials.gov Identifier: NCT00002921|
Recruitment Status : Terminated (Permanently Closed Due to Lack of Accrual)
First Posted : July 30, 2004
Last Update Posted : October 5, 2012
RATIONALE: Some tumors need growth factors produced by the body to keep growing. Suramin may interfere with the growth factor and stop the tumor from growing.
PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with stage III or stage IV adrenocortical cancer.
|Condition or disease||Intervention/treatment||Phase|
|Adrenocortical Carcinoma||Drug: suramin Drug: therapeutic hydrocortisone||Phase 2|
OBJECTIVES: I. Assess the response of patients with adrenocortical carcinoma treated with suramin. II. Evaluate the qualitative and quantitative toxic effects of this therapy.
OUTLINE: Patients are described according to stage, performance status, prior radiotherapy, prior surgery, and prior mitotane therapy. Patients receive suramin IV for 5 days in the first week, then twice a week for 2 weeks, and then weekly for a total of 12 weeks. Hydrocortisone is taken PO twice daily. Following a 12 week rest, patients receive a second course; those with stable or responding disease continue treatment for a maximum of four courses.
PROJECTED ACCRUAL: A maximum of 40 patients will be accrued at a rate of 6-7 per year.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||13 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II|
|Study Start Date :||March 1997|
|Primary Completion Date :||January 2004|
|Study Completion Date :||January 2004|
|Experimental: Suramin||Drug: suramin Drug: therapeutic hydrocortisone|
- Response to suramin [ Time Frame: From date of registration to progression or date of death from any cause, whichever came first, assessed up to four cycles ]
- Number and grade of adverse events [ Time Frame: From date of registration until progression or date of death from any cause, whichever came first, up to four cycles ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002921
Show 65 Study Locations
|Study Chair:||Louis E. Schroder, MD||Barrett Cancer Center|